HistoSonics, headquartered in United States, remains privately held in the medical device space. Its most recent disclosed valuation is $2.2B. Its shares do not trade on a public exchange.
One company valuation: $2.2B, dated Aug 2025.
Medical device company.
Last valuation$2.2BAug 2025
ABC Impact
Founders FundSSunway iLabsABC ImpactFounders FundHistoSonics is a privately held medical device company developing a non-invasive sonic beam therapy platform built on the science of histotripsy. Its Edison System delivers pulsed sound energy through the body without incisions or needles, destroying targeted liver tumors at the sub-cellular level while the treating physician monitors the effect in real time, and the device is restricted to sale by or on the order of a physician.
The company traces its histotripsy work back to a Vortx Rx system for benign prostatic hyperplasia, first developed from a Michigan base, and has since focused on liver tumor treatment while pursuing an FDA submission for kidney tumors. HistoSonics has won recognition including a BioTech Breakthrough Award for Medtech Innovation of the Year.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds HistoSonics.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. HistoSonics availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — HistoSonics included.
The last valuation is $2.2B.
Lead investors for each round are in the funding timeline.
The closest medical device peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
